Dame Siobhain McDonagh @Siobhain_Mc asked the Prime Minister a simple question yesterday: how many glioblastoma patients in the UK are actually on a clinical trial? Nobody knows. Her fear is fewer than 1%.
I have GBM, so I am grateful that she asks. But I would go one step further. The problem is not only access to trials. It is the kind of trial we insist on.
The double-blind, placebo-controlled trial was built to test one drug on thousands of similar patients. GBM is not one disease. Every tumour is different, and it changes under treatment. The therapies that give me hope are personalised, designed around one patientโs tumour. They do not fit the old template, so they wait.
Thirty years without a breakthrough should tell us the standard itself needs to change. The new national brain cancer clinical lead could start there.
Today at PMQs, I asked the Prime Minister why nobody appears to know how many brain tumour patients are taking part in clinical trials.
I fear fewer than 1% are accessing trials.
After 30 years without a breakthrough in treatment, patients cannot afford to wait any longer.
Day 01 of #ValuexME 2026 is underway.
The room is full, the first ideas are on the floor and the questions have already begun.
Here are a few snapshots from the opening of the day.
All day today, investors from around the world will share their best ideas in our signature 6-3-1 format:
- 6 minutes to make their case
- 3 minutes for the room to test it
- 1 takeaway that endures
Idea by idea, question by question, this room is doing what ValuexME was built for: serious investors sharing their best thinking, and peers willing to sharpen it.
Weโre only getting started.
Stay with us through the day for more.
#ValuexME2026 #ValueInvesting #InvestmentIdeas #DubaiEvents
John Crowley (HBS โ97) was told there was no treatment for his two children. He went all in, built two biotechs and now leads @IAmBiotech.
As a fellow HBS grad and investor living with glioblastoma, I know that race against the clock.
Thanks @BeckyQuick.
https://t.co/uYWjyMbVT7 via @YouTube
Beginning in 2009, our #HNL lab (with amazing co-authors) has published papers in PNAS on human social interactions: their structure and function; their deep evolutionary origins; how AI affects them.
A thread on the sociology, economics, and biology of social networks.
@CJHandmer Hi Casey. I share your vision. Many academics do. But transforming an entire collective effort of human-led research is not a simple thing to do, so it makes sense that it will take a while to propagate. In the meantime, we are indeed seeing fruits of major speedups:
A measure of a great man is one who because of his status can engage in endless sexual debauchery but chooses otherwise. To be a high status man and commit solely to a single woman is virtuous temperance. To be with 1,000 women is easy. To wholly love a single woman 100,000 times is divinely better. A happy marriage is the hallmark of a stable and meaningful life.
People ask if Iโve read all the books I own. No, not at all. A private library is not merely a storage facility for once-read books, but a tool box, a spice rack, a medicine cabinet โ an investment in future health and happiness.
Lewis Hamilton: great Ferrari driver, poor geopolitical analyst. Rafah is the EgyptโGaza crossing. Egypt doesn't appear anywhere in his post. https://t.co/TQ2SfOv1IJ
Watch how Formula 1 legend Lewis Hamilton embarrassed himself with a post he published about Gaza. That's what happens when you become a useful idiot for anti-Israel propaganda.
Taleb is my greatest intellectual disappointment.
I read his books years ago. He praises Popper, yet clings to nonsensical libels & lies about Israel.
Instead of revising his views when people like @davidboxenhorn rebut him, he doubles down on his antisemitic rhetoric.